Urol. praxi. 2024;25(4):213-217 | DOI: 10.36290/uro.2024.074

Clinical application of liquid biopsy in uro-oncology

MUDr. Aneta Rozsypalová
Onkologická klinika 1. LF UK a FTN, Praha

The liquid biopsy is a new promising option in diagnosis, monitoring during the treatment and early detection of relapse. A big advantage of liquid biopsy is its mini-invasi­vity, the possibility of frequent repetition and thus real-time monitoring of the disease. This article summarizes the current results of liquid biopsy in urological malignancies.

Keywords: liquid biopsy, free circulating DNA, circulating tumor cells, prostate cancer, bladder cancer, renal carcinoma, testicular tumors.

Accepted: November 11, 2024; Published: November 25, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rozsypalová A. Clinical application of liquid biopsy in uro-oncology. Urol. praxi. 2024;25(4):213-217. doi: 10.36290/uro.2024.074.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 25.11.2025

    References

    1. Kubaczková V, Sedlaříková L, Bešše L, et al. Potenciál volné cirkulující DNA v diagnostice nádorových onemocnění. [Internet] Klin Onkol. 2015;28(4):251-259. [Citace: 15. 5 2024.] DOI: 10.14735/amko2015251. Go to original source... Go to PubMed...
    2. Chehade L, Abdel Sater AH, Kourie HL, et al. Clinical implications of liquid biopsies in urogenital tumors: a narrative review. [Internet] Precision cancer medicine. 2022. https://pcm.amegroups.org/article/view/7288. Go to original source...
    3. BIOGEN PRAHA, s.r.o. BIOGEN, molekulární biologie a genetika. Tekuté biopsie - detekce cirkulující nádorové DNA | Biogen.cz. [Internet] Společnost BIOGEN PRAHA, s.r.o. [Citace: 17. 5 2024.] https://biogen.cz/gatcliquid-detekce-cirkulujici-nadorove-dna-pomoci-tekute-biopsie.
    4. Sugeeta SS, Sharma A, Ng K, et al. Biomarkers in Bladder Cancer Surveillance. [Internet] Front Surg. 202;8:735868. [Citace: 20. 5 2024.] https://doi.org/10.3389/fsurg.2021.735868. Go to original source...
    5. Kulasinghe A, Wu H, Punyadeera C, Warkiani ME. The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy. [Internet] Micromachines. 2018;9(8),397. https://www.mdpi.com/2072-666X/9/8/397. Go to original source... Go to PubMed...
    6. Ústav zdravotnických informací a statistiky, ČR. Novotvary 2019-2021. [Internet] 2023. [Citace: 17. 5 2024.] https://www.uzis.cz/index.php?pg=record&id=8447.
    7. Di Meo A, Bartlett J, Cheng Y, et al. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. [Internet] Mol Cancer. 2017;16(1):80. [Citace: 17. 5 2024.] doi: 10.1186/s12943-017-0644-5. Go to original source... Go to PubMed...
    8. Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. [Internet] J Clin Oncol. 2014;32(11):1136-1142. [Citace: 20. 5 2024.] doi: 10.1200/JCO.2013.51.7417. . Go to original source... Go to PubMed...
    9. Vogelzang NJ, Fizazi K, Burke JM, et al. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. [Internet] Eur Urol. 2017;71(2):168-171. [Citace: 20. 5 2024.] doi: 10.1016/j.eururo.2016.07.051. Go to original source... Go to PubMed...
    10. Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. [Internet] J Clin Oncol. 2015;33(12):1348-1355. [Citace: 20. 5. 2024.] doi: 10.1200/JCO.2014.55.3487. Go to original source... Go to PubMed...
    11. Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. [Internet] Clin Chem. 2009;55:559-567, 2009. [Citace: 18. 5 2024.] doi: 10.1373/clinchem.2008.108498. Go to original source... Go to PubMed...
    12. Mahon KL, Qu W, Devaney J, et al. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemothe­rapy in castrate-resistant prostate cancer. [Internet] Br J Cancer. 2014;111:1802-1809. [Citace: 18. 5 2024.] doi: 10.1038/bjc.2014.463. Go to original source... Go to PubMed...
    13. Horning AM, Awe JA, Wang CM, et al. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. [Internet] Prostate. 2015;75:1790-1801. [Citace: 18. 5 2024.] doi: 10.1002/pros.23052. Go to original source... Go to PubMed...
    14. Li S, Xin K, Pan S, et al. Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer. [Internet] Cell Mol Biol Lett. 2023;28(1):28. [Citace: 19. 5 2024.] doi: 10.1186/s11658-023-00442. Go to original source...
    15. Brunner A, Prelog M, Verdorfer I, et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. [Internet] J Clin Pathol. 2008;61:307-310. [Citace: 20. 5 2024.] doi: 10.1136/jcp.2007.049460. Go to original source... Go to PubMed...
    16. Birkenkamp-Demtröder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. [Internet] Eur Urol. 2018;73:535-554. [Citace: 20. 5 2024.] doi: 10.1016/j.eururo.2017.09.011. Go to original source... Go to PubMed...
    17. Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. [Internet] Nature. 2021;595(7867):432-437. [Citace: 17. 5 2024.]oi: 10.1038/s41586-021-03642-9. Go to original source... Go to PubMed...
    18. Nawaf C, Shiang A, Chauhan PS, et al. Circulating tumor DNA based minimal residual disease detection and adjuvant treat­ment decision-making for muscle-invasive bladder cancer guided by modern clinical trials. [Internet] Transl Oncol. 2023;37:101763. [Citace: 20. 5. 2024.]doi.org/10.1016/j.tranon.2023.101763. Go to original source... Go to PubMed...
    19. Li M, Li L, Zheng Jet al. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. [Internet] Mol Cancer. 2023;22(1):37. [Citace: 20. 5. 2024.] doi.org/10.1186/s12943-023-01745-7. Go to original source... Go to PubMed...
    20. Rozsypalová A. Význam onkomarkerů u testikulárních nádorů. [Internet] Urol. praxi. 2018;19(4):172-175. [Citace: 20. 5. 2024.] DOI: 10.36290/uro.2018.081. Go to original source...
    21. Ellinger J, Wittkamp V, Albers P, et al. Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular GermCell Cancer. [Internet] J Urol. 2009;181(1):363-371. [Citace: 17. 5- 2024.] DOI: 10.1016/j.juro.2008.08.118. Go to original source... Go to PubMed...
    22. Boubliková L, Kramarzova KS, Zwyrtkova M , et al. The clinical value of circulating free tumor DNA in testicular germ cell tumor patients. [Internet] Urol Oncol. 2022;40(9):412. [Citace: 17. 5 2024.] doi.org/10.1016/j.urolonc.2022.04.021. Go to original source... Go to PubMed...
    23. Nappi L, Nichols C, Kollmannsberger C. Game Changer in Testicular Cancer: Is miR371a-3p Primed for Clinical Utility? [Internet] 2023. [Citace: 20. 5 2024.] https://dailynews.ascopubs.org/do/game-changer-testicular-cancer-mir371a-3p-primed-clinical-utility.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.